Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD
- 25 November 2022
- journal article
- research article
- Published by Elsevier BV in Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale
- Vol. 163 (4), 799-814
- https://doi.org/10.1016/j.chest.2022.11.027
Abstract
No abstract availableFunding Information
- Ministry of Science and Technology, Taiwan
This publication has 36 references indexed in Scilit:
- Umeclidinium for the treatment of chronic obstructive pulmonary diseaseExpert Review of Respiratory Medicine, 2014
- Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2014
- Long-acting muscarinic receptor antagonists for the treatment of respiratory diseasePulmonary Pharmacology & Therapeutics, 2013
- β2-Agonist Therapy in Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- The Efficacy and Safety of the Novel Long-Acting β 2 Agonist Vilanterol in Patients With COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespiratory Research, 2011
- Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- The cardiovascular risk of tiotropium: is it real?Expert Opinion on Drug Safety, 2010
- Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulationsBiometrical Journal, 2009
- Assessing balance in measured baseline covariates when using many‐to‐one matching on the propensity‐scorePharmacoepidemiology and Drug Safety, 2008